IOVANCE CCO has 10,001 RSUs vest into shares

IOVANCE BIOTHERAPEUTICS, INC. reported that Chief Commercial Officer Kirby Daniel Gordon had 10,001 Restricted Stock Units vest and convert into an equal number of common shares on August 10, 2026.

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS, INC. reported that Chief Commercial Officer Kirby Daniel Gordon had 10,001 Restricted Stock Units vest and convert into an equal number of common shares on August 10, 2026. Of these, 2,436 shares were delivered or withheld at $6.40 per share to satisfy mandatory tax withholding, which was not an open-market sale. Following the vesting, Gordon held 60,003 RSUs from the February 10, 2025 grant, with the remaining units scheduled to vest in equal quarterly installments.

Insider Trade Summary

10,001 shares exercised/converted

Exercise 3 txns

Insider Kirby Daniel Gordon

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F4, F5, F6	10,001	$0.00	$0.00
Exercise	Common Stock F1	10,001	$0.00	$0.00
Tax Withholding	Common Stock F2, F3	2,436	$6.40	$16K

Holdings After Transaction: Restricted Stock Units — 60,003 contracts (Direct); Common Stock — 154,511 shares (Direct)

Footnotes (6)

1. F1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
2. F2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
3. F3. Represents the common stock remaining after deducting the common stock withheld for taxes.
4. F4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
5. F5. The remaining RSUs will vest in equal quarterly installments.
6. F6. Such aggregate number reflects the remainder of such RSUs granted on February 10, 2025, but does not include any other RSUs held by such Reporting Person.

Key Figures

RSUs vested: 10,001 units Shares withheld for taxes: 2,436 shares Withholding price: $6.40 per share +2 more

5 metrics

RSUs vested 10,001 units Restricted Stock Units vested and converted into common stock on August 10, 2026

Shares withheld for taxes 2,436 shares Common shares delivered or withheld to satisfy mandatory tax withholding upon RSU vesting

Withholding price $6.40 per share Price used for shares delivered or withheld for tax liability

Remaining RSUs from 2025 grant 60,003 units RSUs remaining from February 10, 2025 grant after current vesting event

Exercise/vesting shares 10,001 shares Common stock received upon RSU vesting on August 10, 2026

Key Terms

Restricted Stock Units, mandatory tax withholding requirements, contingent right, vesting in equal quarterly installments

4 terms

Restricted Stock Units financial

"Represents such shares underlying the restricted stock units ("RSUs") which vested"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding requirements financial

"shares withheld by the Issuer to satisfy the mandatory tax withholding requirements"

contingent right financial

"Each RSU represents a contingent right to receive one share"

vesting in equal quarterly installments financial

"The remaining RSUs will vest in equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IOVANCE BIOTHERAPEUTICS (IOVA) report for Kirby Daniel Gordon?

IOVANCE BIOTHERAPEUTICS reported that Chief Commercial Officer Kirby Daniel Gordon had 10,001 RSUs vest into common stock on August 10, 2026. These RSUs converted 1-for-1 into common shares as part of his equity compensation.

How many IOVA shares were withheld for taxes in the latest Form 4?

In the latest Form 4, 2,436 common shares of IOVANCE BIOTHERAPEUTICS were delivered or withheld at $6.40 per share to satisfy mandatory tax withholding upon RSU vesting. This tax settlement was not an open-market sale.

What is the resulting RSU position for Kirby Daniel Gordon at IOVANCE (IOVA)?

After the reported vesting, Kirby Daniel Gordon held 60,003 RSUs from the February 10, 2025 grant. This figure reflects the remaining units from that grant only and excludes any other RSUs he may hold.

Did the IOVA Form 4 report an open-market stock sale by Kirby Daniel Gordon?

The Form 4 did not report any open-market stock sale by Kirby Daniel Gordon. The 2,436 shares disposed were expressly described as shares withheld by the issuer solely to satisfy mandatory tax withholding on vested RSUs.

What does each RSU reported by IOVANCE BIOTHERAPEUTICS (IOVA) represent?

Each RSU reported for Kirby Daniel Gordon represents a contingent right to receive one share of IOVANCE BIOTHERAPEUTICS common stock. As RSUs vest, they convert on a 1-for-1 basis into common shares, subject to applicable tax withholding.

How will the remaining RSUs for Kirby Daniel Gordon at IOVA vest over time?

The remaining RSUs from the February 10, 2025 grant to Kirby Daniel Gordon will vest in equal quarterly installments. This schedule gradually delivers common shares over time, contingent on continued service and subject to tax withholding at each vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 05:30 PM Accepted by SEC EDGAR 08/12/2026 - 05:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirby Daniel Gordon

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/10/2026(1)		M		10,001	A	$0	156,947	D
Common Stock	08/10/2026(2)		F		2,436	D	$6.4	154,511(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(4)	08/10/2026		M			10,001	(5)	(5)	Common Stock	10,001	$0.00	60,003(6)	D

Explanation of Responses:

1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.

2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.

3. Represents the common stock remaining after deducting the common stock withheld for taxes.

4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

5. The remaining RSUs will vest in equal quarterly installments.

6. Such aggregate number reflects the remainder of such RSUs granted on February 10, 2025, but does not include any other RSUs held by such Reporting Person.

	/s/ Daniel Gordon Kirby	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)